ICU admission for solid cancer patients treated with immune checkpoint inhibitors.
Fiche publication
Date publication
avril 2023
Journal
Annals of intensive care
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier
Tous les auteurs :
Toffart AC, Meert AP, Wallet F, Gibelin A, Guisset O, Gonzalez F, Seguin A, Kouatchet A, Delaunay M, Debieuvre D, Duchemann B, Rousseau-Bussac G, Nyunga M, Grimaldi D, Levrat A, Azoulay E, Lemiale V
Lien Pubmed
Résumé
Immune checkpoint inhibitors (ICI) have revolutionized the management of cancer. They can induce immune-related adverse events (irAE) leading to intensive care unit (ICU) admission. We aimed to describe irAEs for ICU admissions in solid cancer patients treated with ICIs.
Mots clés
Immune checkpoint inhibitor, Immune-related adverse event, Intensive care, Solid tumor
Référence
Ann Intensive Care. 2023 04 18;13(1):29